Good morning. Good morning, ladies and gentlemen. Please go ahead, sir. Thank you. Sorry. Good morning, ladies and gentlemen. I'm John Duke, President and Chief Executive Officer of Harvard Bioscience. It is my pleasure to preside over our company's 2026 annual meeting. I will act as chairman of this meeting. We are pleased to be once again hosting our meeting using a virtual-only format, which allows our shareholders to participate in the meeting through a convenient online portal. This meeting is officially called to order. I would like to start by acknowledging the other directors of the company who are present today: Katherine Eade, Robert Gagnon, Seth Benson, Stephen DeNelsky, William Snyder. I would also like to note that Anden Utzinger from our independent auditor, Grant Thornton, and Megan Gates from our outside legal counsel, Covington & Burling, are also in attendance at today's meeting. A notice of the meeting was sent to all stockholders of record as of the close of business on April 7th, 2026, the record date of this meeting. Only stockholders of record on that date are entitled to vote. I have been informed by an inspector of elections that one-third of the voting power of our outstanding common stock is present by remote communication or represented by proxy. Based on that information, I therefore declare that a quorum exists, and this meeting is duly constituted for the transaction of business. Stockholders who would like to ask questions or offer comments pertaining to the agenda items being considered at today's meeting may do so now through the web portal. If you have previously voted online, by phone, or by signing and returning a proxy card, you do not need to vote again at today's meeting unless you would like to change your vote. The polls are now open for voting through the web portal. Stockholders who would like to vote at today's meeting may do so now by clicking on the voting buttons on the web portal and following the instructions there. The polls will close following the discussion of today's business items. The meeting agenda and rules are available on the web portal. We are pleased to present five business items for consideration. The first item is the election of two Class II directors, each for a three-year term, continuing until the 2029 annual meeting of stockholders and until the directors' successors are duly elected and qualified. As described in the proxy statement made available to stockholders in connection with this meeting, our board has nominated and has recommended that our shareholders vote for Katherine Eade and myself, John Duke, to serve as the Class II directors of the company. The affirmative vote of a plurality of the votes cast at this meeting is required for the election of Katherine Eade and myself. Stockholders may vote for the nominated directors or abstain from voting. The second item is the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. The affirmative vote of the majority of the votes cast is required for the ratification of the appointment of Grant Thornton. Stockholders may vote for, against, or abstain from voting on this proposal. Our board has recommended that our stockholders vote for the ratification of Grant Thornton. The third item is the approval by a non-binding advisory vote of the compensation of Harvard Bioscience's named executive officers. The affirmative vote of a majority of the votes cast is required for the approval of this non-binding proposal. Stockholders may vote for, against, or abstain. Our board has recommended that our stockholders vote for this proposal. The fourth item is the approval of an amendment to our employee stock purchase plan to increase the number of common shares available for issuance under the plan. The affirmative vote of a majority of the votes cast is required for the approval of this item. Stockholders may vote for, against, or abstain. Our board has recommended that our stockholders vote for this proposal. The fifth and final item is the approval of our amended and restated 2021 incentive plan to increase the number of common shares available for issuance under the plan. The affirmative vote of a majority of the votes cast is required for approval of this item. Stockholders may vote for, against, or abstain. Our board has recommended that our stockholders vote for this proposal. If a stockholder would like to make a comment regarding any of the proposals, please submit your comment through the web portal. There being no further discussion regarding the proposals, we will now proceed to vote. Any stockholder still wishing to vote should do so now. If you have already sent in a proxy or voted via telephone or internet and do not wish to change your vote, you do not need to take any further action. Now that everyone has had the opportunity to vote, I now declare the polls closed. I can now present the voting results received from our inspector of elections. First, I am pleased to report that a plurality of the votes cast at this meeting has been voted in favor of the election of Katherine Eade and myself, John Duke, as our Class II directors for three-year terms until the 2029 annual meeting of stockholders and until our successors are duly elected and qualified. On the second item, a majority of the votes cast have been voted in favor of the ratification of the appointment of Grant Thornton as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. Third, a majority of the votes cast have been voted to approve the compensation of our named executive officers. Fourth, a majority of the votes cast have been voted in favor of the amendment to the employee stock purchase plan. As to the fifth and final item, a majority of the votes cast have been voted in favor of the amended and restated 2021 incentive plan. Complete voting results will be filed with the Form 8-K that will be posted on the sec.gov website following the tabulation of the final voting results. That concludes the business items for today's consideration at today's meeting. Thank you for your participation. The meeting is now adjourned. This now concludes the meeting. Thank you for joining. Have a pleasant day.